Taysha Gene Therapies: Rett Syndrome Data Makes This A Must Watch (NASDAQ:TSHA)
nuttapong punna/iStock via Getty Images Taysha Gene Therapies (NASDAQ:TSHA) has made great progress recently in advancing its gene therapy known as TSHA-102 for the treatment of patients with Rett Syndrome. Despite only having data from one patient so far, with a second expected to start dosing in Q3 of 2023, the data shown thus far…